Alpha-Synuclein is degraded by both autophagy and the proteasome
- PMID: 12719433
- DOI: 10.1074/jbc.M300227200
Alpha-Synuclein is degraded by both autophagy and the proteasome
Abstract
Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra and the formation of aggregates (Lewy bodies) in neurons. alpha-Synuclein is the major protein in Lewy bodies and rare mutations in alpha-synuclein cause early-onset PD. Consequently, alpha-synuclein is implicated in the pathogenesis of PD. Here, we have investigated the degradation pathways of alpha-synuclein, using a stable inducible PC12 cell model, where the expression of exogenous human wild-type, A30P, or A53T alpha-synuclein can be switched on and off. We have used a panel of inhibitors/stimulators of autophagy and proteasome function and followed alpha-synuclein degradation in these cells. We found that not only is alpha-synuclein degraded by the proteasome, but it is also degraded by autophagy. A role for autophagy was further supported by the presence of alpha-synuclein in organelles with the ultrastructural features of autophagic vesicles. Since rapamycin, a stimulator of autophagy, increased clearance of alpha-synuclein, it merits consideration as a potential therapeutic for Parkinsons disease, as it is designed for chronic use in humans.
Similar articles
-
Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death.J Neurosci. 2001 Dec 15;21(24):9549-60. doi: 10.1523/JNEUROSCI.21-24-09549.2001. J Neurosci. 2001. PMID: 11739566 Free PMC article.
-
Degradation of alpha-synuclein by proteasome.J Biol Chem. 1999 Nov 26;274(48):33855-8. doi: 10.1074/jbc.274.48.33855. J Biol Chem. 1999. PMID: 10567343
-
Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis.Hum Mol Genet. 2001 Apr 15;10(9):919-26. doi: 10.1093/hmg/10.9.919. Hum Mol Genet. 2001. PMID: 11309365
-
[Parkinson's disease: what have we learned from the genes responsible for familial forms?].Med Sci (Paris). 2003 May;19(5):613-9. doi: 10.1051/medsci/2003195613. Med Sci (Paris). 2003. PMID: 12836396 Review. French.
-
[Parkin, alpha-synuclein and other molecular aspects of Parkinson's disease].J Soc Biol. 2002;196(1):95-10. J Soc Biol. 2002. PMID: 12134640 Review. French.
Cited by
-
Small Molecules, α-Synuclein Pathology, and the Search for Effective Treatments in Parkinson's Disease.Int J Mol Sci. 2024 Oct 18;25(20):11198. doi: 10.3390/ijms252011198. Int J Mol Sci. 2024. PMID: 39456980 Free PMC article. Review.
-
Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies.Cell Mol Life Sci. 2024 Sep 3;81(1):382. doi: 10.1007/s00018-024-05419-5. Cell Mol Life Sci. 2024. PMID: 39223418 Free PMC article. Review.
-
Nuclear proteasomes buffer cytoplasmic proteins during autophagy compromise.Nat Cell Biol. 2024 Oct;26(10):1691-1699. doi: 10.1038/s41556-024-01488-7. Epub 2024 Aug 29. Nat Cell Biol. 2024. PMID: 39209961 Free PMC article.
-
Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington's disease (FELL-HD): a phase II, single-centre, open-label, dose-finding trial protocol.BMJ Open. 2024 Aug 21;14(8):e087983. doi: 10.1136/bmjopen-2024-087983. BMJ Open. 2024. PMID: 39174070 Free PMC article. Clinical Trial.
-
The prion-like effect and prion-like protein targeting strategy in amyotrophic lateral sclerosis.Heliyon. 2024 Jul 22;10(15):e34963. doi: 10.1016/j.heliyon.2024.e34963. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170125 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
